# ASP Isotopes Inc. Common Stock (ASPI.US)

Canonical: https://gigainvestors.com/s/ASPI

Analysis as of: 2026-10-16T07:26:37.528Z. 

Listing currency: USD. Reporting currency: USD.

## Verdict

Not enough history yet

Quality tests for Buy: not passed (profit record: fail; earnings resilience is evidence only). Published buy qualification: no.

Share price: $2.21 per share; close as of 2026-10-15.

## Checklist

### understandable: na

### moat: na

### economics: na

### management: na

### accounting: na

## Holders

- [Dan Davidowitz](https://gigainvestors.com/pcm): tracked 13F investor; follow the investor page for holding quarter and amounts.

## Price story

Down 78% since Oct 2025

Story as of 2026-10-16T10:01:29.602Z; price observation 2026-10-15.

## Owner memo

Memo as of 2026-10-16T08:06:05.509Z.

### How it makes money

Operates in specialty chemicals; annual sales are USD 23.8 million.

- Source: https://www.sec.gov/Archives/edgar/data/1921865/000119312526151294/aspi-20251231.htm (filed 2026-04-10); FY2025: revenue 23849000; grossProfit 3405000; margin = grossProfit / revenue.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-05); ASPI.US: ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.

### Why customers stay

Margins ranged from 14.3% to 38.6% during 2023–25.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-04-10); FY2023: grossProfit / revenue = 32.1%.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-04-10); FY2024: grossProfit / revenue = 38.6%.

- Source: https://www.sec.gov/Archives/edgar/data/1921865/000119312526151294/aspi-20251231.htm (filed 2026-04-10); FY2025: grossProfit / revenue = 14.3%.

### Where the cash goes

Paid dividends in 1 of 5 years.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-04-10); Dividend observations: [[2021,0],[2022,0],[2023,0],[2024,2779659],[2025,0]]. Zero only counted when supported by a complete cash-flow statement.

### Are managers owners

Insiders own 10.5% of the company.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-05); ASPI.US SharesStats.PercentInsiders = 10.504 percentage points; cache date 2026-10-05.

### What the price says

The price is 7.7 times annual sales; cash earnings are negative.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-04-10); Closing price 2.21 USD; reporting-to-trading FX 1; FY2025 annual sales per share 0.28729029609295076; price multiple 7.692567518134932. FY2025 cash earnings/share -2.1091967178291307. Closing-price date 2026-10-15.

## Monthly share-price history (USD per share)

- 2022-11: $2.14 per share

- 2022-12: $1.58 per share

- 2023-01: $1.56 per share

- 2023-02: $1.80 per share

- 2023-03: $0.85 per share

- 2023-04: $0.64 per share

- 2023-05: $0.32 per share

- 2023-06: $0.57 per share

- 2023-07: $1.11 per share

- 2023-08: $1.20 per share

- 2023-09: $0.95 per share

- 2023-10: $1.11 per share

- 2023-11: $1.92 per share

- 2023-12: $1.79 per share

- 2024-01: $2.45 per share

- 2024-02: $3.81 per share

- 2024-03: $4.13 per share

- 2024-04: $3.17 per share

- 2024-05: $5.11 per share

- 2024-06: $3.06 per share

- 2024-07: $2.65 per share

- 2024-08: $2.37 per share

- 2024-09: $2.78 per share

- 2024-10: $6.99 per share

- 2024-11: $5.55 per share

- 2024-12: $4.53 per share

- 2025-01: $5.75 per share

- 2025-02: $4.76 per share

- 2025-03: $4.69 per share

- 2025-04: $5.28 per share

- 2025-05: $7.56 per share

- 2025-06: $7.36 per share

- 2025-07: $9.07 per share

- 2025-08: $9.28 per share

- 2025-09: $9.62 per share

- 2025-10: $10.13 per share

- 2025-11: $6.22 per share

- 2025-12: $5.35 per share

- 2026-01: $6.34 per share

- 2026-02: $5.34 per share

- 2026-03: $4.42 per share

- 2026-04: $5.26 per share

- 2026-05: $7.78 per share

- 2026-06: $6.22 per share

- 2026-07: $4.00 per share

- 2026-08: $4.02 per share

- 2026-09: $2.65 per share

- 2026-10: $2.21 per share

## Annual estimated value (USD per share)

Historical values use today's bond yield for every fiscal year

Historical values use today's FX rate into trading currency for every fiscal year

Historical values use current restated fundamentals and current commodity classification; they are not point-in-time estimates

## Sources

[Original 10-K filing](https://www.sec.gov/Archives/edgar/data/1921865/000119312526151294/aspi-20251231.htm); period 2025-12-31, filed 2026-04-10.

Estimates depend on assumptions and are not guarantees or investment advice. Underlying data remains subject to its source licenses; public reading does not grant bulk redistribution rights.